Abstract
New methods in the systemic treatment of ovarian cancer are investigated for prolonging progression free interval and overall survival and improving prognosis of the patients with ovarian cancer. The targeted molecular biological therapy has achieved the most progress.
Increasing knowledge of the internal molecular processes, understanding of the transmission of information within the cell and the recognition of cellular receptors and the are the principles of use and success of biological treatment. The basic parts of targeted treatment are low-molecular-weight receptor tyrosine kinase inhibitors and monoclonal antibodies.